Latanoprost Olikla

Latanoprost, the active ingredient in Latanoprost Olikla, is a prostaglandin analog presented as a ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used to treat open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latanoprost Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost belongs to the prostaglandin analog class and is indicated for conditions that require reduction of intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Pseudoexfoliative glaucoma: decreases pressure to protect optic nerve function.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness (hyperemia) - Increased eyelash length and thickness - Darkening of the iris (iris pigmentation) - Eye irritation or foreign‑body sensation - Blurred vision shortly after instillation - Periocular skin darkening

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Corneal edema or keratitis - Uveitis or intra‑ocular inflammation - Vision loss due to optic nerve compromise - Persistent ocular pain or photophobia

Before initiating therapy, clinicians should evaluate ocular health and consider patient‑specific factors. - Monitor intra‑ocular pressure: schedule regular IOP measurements. - Assess for ocular infections: avoid use if active conjunctivitis or keratitis is present. - Discontinue contact lens wear: advise patients to remove lenses during treatment. - Caution in uveitic eyes: monitor closely for inflammation. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concomitant use of other prostaglandin analog eye drops: may increase risk of ocular hyperemia and pigmentation changes. - Simultaneous administration of non‑steroidal anti‑inflammatory eye drops: can diminish latanoprost's IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction may require monitoring. - Topical corticosteroids: may reduce latanoprost efficacy. - Systemic antihistamines: possible decreased response to therapy.